Lovely Goyal

1.8k total citations
28 papers, 510 citations indexed

About

Lovely Goyal is a scholar working on Oncology, Immunology and Rheumatology. According to data from OpenAlex, Lovely Goyal has authored 28 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 9 papers in Immunology and 5 papers in Rheumatology. Recurrent topics in Lovely Goyal's work include CAR-T cell therapy research (16 papers), Biosimilars and Bioanalytical Methods (8 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Lovely Goyal is often cited by papers focused on CAR-T cell therapy research (16 papers), Biosimilars and Bioanalytical Methods (8 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Lovely Goyal collaborates with scholars based in United States, France and United Kingdom. Lovely Goyal's co-authors include David S. Hong, Patricia LoRusso, Roy S. Herbst, Razelle Kurzrock, Sattva S. Neelapu, Yuying C. Hwang, F. Susan Wong, Cheng‐Pang Hsu, Greg Friberg and John S. Hill and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Lovely Goyal

28 papers receiving 497 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lovely Goyal United States 12 339 224 142 75 65 28 510
Xinjie Xu United States 9 290 0.9× 160 0.7× 99 0.7× 118 1.6× 58 0.9× 35 483
Erik F. Williams United States 3 388 1.1× 170 0.8× 224 1.6× 76 1.0× 42 0.6× 4 556
Olli Dufva Finland 13 321 0.9× 303 1.4× 247 1.7× 52 0.7× 53 0.8× 31 719
Michael Jeffrey Cho United States 7 334 1.0× 261 1.2× 232 1.6× 109 1.5× 176 2.7× 8 779
Mingqing Zhu China 11 439 1.3× 246 1.1× 380 2.7× 101 1.3× 36 0.6× 53 809
Ekaterina Zmievskaya Russia 10 291 0.9× 166 0.7× 177 1.2× 75 1.0× 21 0.3× 18 452
Jessica Foster United States 11 217 0.6× 181 0.8× 87 0.6× 95 1.3× 22 0.3× 26 447
Ian R. Hardy United States 7 423 1.2× 185 0.8× 161 1.1× 104 1.4× 59 0.9× 10 556
S. M. Luger United States 8 372 1.1× 407 1.8× 274 1.9× 88 1.2× 45 0.7× 14 949
Sunil S. Raikar United States 13 405 1.2× 205 0.9× 252 1.8× 111 1.5× 55 0.8× 37 639

Countries citing papers authored by Lovely Goyal

Since Specialization
Citations

This map shows the geographic impact of Lovely Goyal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lovely Goyal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lovely Goyal more than expected).

Fields of papers citing papers by Lovely Goyal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lovely Goyal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lovely Goyal. The network helps show where Lovely Goyal may publish in the future.

Co-authorship network of co-authors of Lovely Goyal

This figure shows the co-authorship network connecting the top 25 collaborators of Lovely Goyal. A scholar is included among the top collaborators of Lovely Goyal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lovely Goyal. Lovely Goyal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Locke, Frederick L., Lazaros J. Lekakis, Herbert Eradat, et al.. (2023). Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).. Journal of Clinical Oncology. 41(16_suppl). 2517–2517. 14 indexed citations
2.
Wayne, Alan S., Van Huynh, Nobuko Hijiya, et al.. (2022). Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica. 108(3). 747–760. 26 indexed citations
3.
4.
Chávez, Julio C., Caron A. Jacobson, Alison R. Sehgal, et al.. (2021). Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5.. Journal of Clinical Oncology. 39(15_suppl). 7548–7548. 5 indexed citations
5.
Neelapu, Sattva S., Rajneesh Nath, Javier Muñoz, et al.. (2021). ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T. Blood. 138(Supplement 1). 3878–3878. 35 indexed citations
6.
Lekakis, Lazaros J., Frederick L. Locke, Michael Tees, et al.. (2021). ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing. Blood. 138(Supplement 1). 649–649. 34 indexed citations
7.
Chávez, Julio C., Caron A. Jacobson, Alison R. Sehgal, et al.. (2021). Retreatment with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) in Zuma-5. Transplantation and Cellular Therapy. 27(3). S43–S43. 1 indexed citations
8.
9.
Tarrant, Jacqueline M., René Galien, Wanying Li, et al.. (2020). Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials. Rheumatology and Therapy. 7(1). 173–190. 27 indexed citations
10.
Bridgewater, John, Funda Meric‐Bernstam, Antoine Hollebecque, et al.. (2020). 54P Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2). Annals of Oncology. 31. S261–S262. 14 indexed citations
11.
Neelapu, Sattva S., Michael Dickinson, Matthew L. Ulrickson, et al.. (2020). Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL). Blood. 136(Supplement 1). 49–49. 34 indexed citations
12.
Chávez, Julio C., Caron A. Jacobson, Alison R. Sehgal, et al.. (2020). Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5. Blood. 136(Supplement 1). 34–34. 6 indexed citations
13.
14.
Neelapu, Sattva S., Mohamed A. Kharfan‐Dabaja, Olalekan O. Oluwole, et al.. (2019). A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14). Blood. 134(Supplement_1). 4093–4093. 7 indexed citations
15.
Neelapu, Sattva S., Julio C. Chávez, Yi Lin, et al.. (2019). ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).. Journal of Clinical Oncology. 37(15_suppl). TPS7574–TPS7574. 2 indexed citations
16.
Flinn, Ian W., William G. Wierda, Steven Coutré, et al.. (2019). ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 37(15_suppl). TPS7566–TPS7566. 6 indexed citations
17.
18.
Keshav, Satish, Xavier Roblin, Geert D’Haens, et al.. (2018). PTU-003 Filgotinib decreases inflammatory markers associated with endoscopic improvement in moderate to severely active crohn’s disease. A63.2–A64. 1 indexed citations
19.
Herbst, Roy S., Razelle Kurzrock, David S. Hong, et al.. (2010). A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 16(23). 5883–5891. 111 indexed citations
20.
Younes, Anas, Mark Kirschbaum, Lubomir Sokol, et al.. (2009). Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.. Blood. 114(22). 1708–1708. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xinjie Xu Breakdown of academic impact, for papers by Erik F. Williams Breakdown of academic impact, for papers by Olli Dufva Breakdown of academic impact, for papers by Michael Jeffrey Cho Breakdown of academic impact, for papers by Mingqing Zhu Breakdown of academic impact, for papers by Ekaterina Zmievskaya Breakdown of academic impact, for papers by Jessica Foster Breakdown of academic impact, for papers by Ian R. Hardy Breakdown of academic impact, for papers by S. M. Luger Breakdown of academic impact, for papers by Sunil S. Raikar
Rankless by CCL
2026